Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCA | P17252 | 1/20 | 0.47 |
| ▸ | MMP12 | P39900 | 1/20 | 0.47 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.40 |
| ▸ | SCN9A | Q15858 | 6/20 | 0.36 |
| ▸ | CCKBR | P32239 | 3/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL923665 | 0.91 | NR1I2 (0.40) | PRKCAMMP12NR1I2SCN9AL3MBTL1 | |
| SCHEMBL923616 | 0.86 | NR1I2 (0.57) | PRKCAMMP12NR1I2SCN9ACYP3A4 | |
| SCHEMBL924086 | 0.84 | PRKCA (0.47) | PRKCAMMP12NR1I2SCN9ACCKBR | |
| SCHEMBL923609 | 0.84 | PRKCA (0.47) | PRKCAMMP12NR1I2SCN9ACCKBR | |
| SCHEMBL923556 | 0.83 | PRKCA (0.48) | PRKCAMMP12NR1I2SCN9ACCKBR | |
| SCHEMBL4822919 | 0.80 | PRKCA (0.51) | PRKCAMMP12NR1I2SCN9ACCKBR | |
| SCHEMBL14435955 | 0.78 | PRKCA (0.49) | PRKCAMMP12NR1I2SCN9ACCKBR | |
| SCHEMBL772286 | 0.78 | PRKCA (0.54) | PRKCAMMP12NR1I2SCN9ACYP3A4 | |
| SCHEMBL804071 | 0.78 | PRKCA (0.53) | PRKCAMMP12NR1I2SCN9ACCKBR | |
| SCHEMBL3571775 | 0.77 | PRKCA (0.52) | PRKCAMMP12NR1I2SCN9ACCKBR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8431568-B2 | Aromatic heterocyclic fused indolobenzadiazepine HCV NS5B inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-04-30 | — | — | US | disclosed |
| US-8431568-B2 | Aromatic heterocyclic fused indolobenzadiazepine HCV NS5B inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-04-30 | — | — | US | disclosed |
| US-8431568-B2 | Aromatic heterocyclic fused indolobenzadiazepine HCV NS5B inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-04-30 | — | — | US | disclosed |
| EP-2278977-B1 | AROMATIC HETEROCYCLIC FUSED INDOLOBENZADIAZEPINE HCV NS5B INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2011-11-02 | — | — | EP | disclosed |
| EP-2278977-B1 | AROMATIC HETEROCYCLIC FUSED INDOLOBENZADIAZEPINE HCV NS5B INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2011-11-02 | — | — | EP | disclosed |
| US-20110014154-A1 | Aromatic Heterocyclic Fused Indolobenzadiazepine HCV NS5B Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2011-01-20 | — | — | US | disclosed |
| US-20110014154-A1 | Aromatic Heterocyclic Fused Indolobenzadiazepine HCV NS5B Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2011-01-20 | — | — | US | disclosed |
| US-20110014154-A1 | Aromatic Heterocyclic Fused Indolobenzadiazepine HCV NS5B Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2011-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110014154-A1 | Aromatic Heterocyclic Fused Indolobenzadiazepine HCV NS5B Inhibitors | HAVCR2, NSD2, ZC3HAV1 | PRKCA 3911/4885MMP12 4743/4885NR1I2 246/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.